SGMO PE Ratio & Valuation,Is SGMO Overvalued

SGMO Relative Valuation

SGMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGMO is overvalued; if below, it's undervalued.

Historical Valuation

Sangamo Therapeutics Inc (SGMO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.44 is considered Undervalued compared with the five-year average of -4.33. The fair price of Sangamo Therapeutics Inc (SGMO) is between 1.14 to 3.66 according to relative valuation methord. Compared to the current price of 0.45 USD , Sangamo Therapeutics Inc is Undervalued By 60.53%.

Relative Value

Fair Zone

1.14-3.66

Current Price：0.45

60.53%

Undervalued

-2.25

-2.03

EV/EBITDA

Sangamo Therapeutics Inc. (SGMO) has a current EV/EBITDA of -2.03. The 5-year average EV/EBITDA is 1.13. The thresholds are as follows: Strongly Undervalued below -51.24, Undervalued between -51.24 and -25.06, Fairly Valued between 27.32 and -25.06, Overvalued between 27.32 and 53.51, and Strongly Overvalued above 53.51. The current Forward EV/EBITDA of -2.03 falls within the Historic Trend Line -Fairly Valued range.

-4.52

EV/EBIT

Sangamo Therapeutics Inc. (SGMO) has a current EV/EBIT of -4.52. The 5-year average EV/EBIT is -2.53. The thresholds are as follows: Strongly Undervalued below -7.45, Undervalued between -7.45 and -4.99, Fairly Valued between -0.06 and -4.99, Overvalued between -0.06 and 2.40, and Strongly Overvalued above 2.40. The current Forward EV/EBIT of -4.52 falls within the Historic Trend Line -Fairly Valued range.

1.44

Sangamo Therapeutics Inc. (SGMO) has a current PS of 1.44. The 5-year average PS is 6.41. The thresholds are as follows: Strongly Undervalued below -3.70, Undervalued between -3.70 and 1.36, Fairly Valued between 11.47 and 1.36, Overvalued between 11.47 and 16.53, and Strongly Overvalued above 16.53. The current Forward PS of 1.44 falls within the Historic Trend Line -Fairly Valued range.

-2.89

P/OCF

Sangamo Therapeutics Inc. (SGMO) has a current P/OCF of -2.89. The 5-year average P/OCF is -4.37. The thresholds are as follows: Strongly Undervalued below -10.83, Undervalued between -10.83 and -7.60, Fairly Valued between -1.14 and -7.60, Overvalued between -1.14 and 2.09, and Strongly Overvalued above 2.09. The current Forward P/OCF of -2.89 falls within the Historic Trend Line -Fairly Valued range.

-2.50

P/FCF

Sangamo Therapeutics Inc. (SGMO) has a current P/FCF of -2.50. The 5-year average P/FCF is -4.31. The thresholds are as follows: Strongly Undervalued below -14.76, Undervalued between -14.76 and -9.54, Fairly Valued between 0.91 and -9.54, Overvalued between 0.91 and 6.13, and Strongly Overvalued above 6.13. The current Forward P/FCF of -2.50 falls within the Historic Trend Line -Fairly Valued range.

Sangamo Therapeutics Inc (SGMO) has a current Price-to-Book (P/B) ratio of 23.25. Compared to its 3-year average P/B ratio of 7.00 , the current P/B ratio is approximately 232.34% higher. Relative to its 5-year average P/B ratio of 5.31, the current P/B ratio is about 337.86% higher. Sangamo Therapeutics Inc (SGMO) has a Forward Free Cash Flow (FCF) yield of approximately -50.45%. Compared to its 3-year average FCF yield of -116.85%, the current FCF yield is approximately -56.82% lower. Relative to its 5-year average FCF yield of -76.38% , the current FCF yield is about -33.94% lower.

23.25

P/B

Median3y

7.00

Median5y

5.31

-50.45

FCF Yield

Median3y

-116.85

Median5y

-76.38

Competitors Valuation Multiple

The average P/S ratio for SGMO's competitors is 11.17, providing a benchmark for relative valuation. Sangamo Therapeutics Inc Corp (SGMO) exhibits a P/S ratio of 1.44, which is -87.09% above the industry average. Given its robust revenue growth of -98.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SGMO decreased by 55.88% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from 0.00 to -1.01.

The secondary factor is the Revenue Growth, contributed -98.82%to the performance.

Overall, the performance of SGMO in the past 1 year is driven by P/E Change. Which is more unsustainable.

-98.82%

49.41M → 581.00K

Revenue Growth

-27933.56%

21.60 → -6.01K

Margin Expansion

27976.50%

0.00 → -1.01

P/E Change

-55.88%

1.02 → 0.45

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Sangamo Therapeutics Inc (SGMO) currently overvalued or undervalued?

What is Sangamo Therapeutics Inc (SGMO) fair value?

SGMO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sangamo Therapeutics Inc (SGMO) is between 1.14 to 3.66 according to relative valuation methord.

How does SGMO's valuation metrics compare to the industry average?

What is the current P/B ratio for Sangamo Therapeutics Inc (SGMO) as of Dec 15 2025?

As of Dec 15 2025, Sangamo Therapeutics Inc (SGMO) has a P/B ratio of 23.25. This indicates that the market values SGMO at 23.25 times its book value.

What is the current FCF Yield for Sangamo Therapeutics Inc (SGMO) as of Dec 15 2025?

As of Dec 15 2025, Sangamo Therapeutics Inc (SGMO) has a FCF Yield of -50.45%. This means that for every dollar of Sangamo Therapeutics Inc’s market capitalization, the company generates -50.45 cents in free cash flow.

What is the current Forward P/E ratio for Sangamo Therapeutics Inc (SGMO) as of Dec 15 2025?

As of Dec 15 2025, Sangamo Therapeutics Inc (SGMO) has a Forward P/E ratio of -2.25. This means the market is willing to pay $-2.25 for every dollar of Sangamo Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sangamo Therapeutics Inc (SGMO) as of Dec 15 2025?

As of Dec 15 2025, Sangamo Therapeutics Inc (SGMO) has a Forward P/S ratio of 1.44. This means the market is valuing SGMO at $1.44 for every dollar of expected revenue over the next 12 months.

SGMO Valuation